Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) was $1.42 for the day, down -0.70% from the previous closing price of $1.43. In other words, the price has decreased by $-0.70 from its previous closing price. On the day, 0.54 million shares were traded. ZNTL stock price reached its highest trading level at $1.535 during the session, while it also had its lowest trading level at $1.405.
Ratios:
Our analysis of ZNTL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.32 and its Current Ratio is at 7.32. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 06 ’25 when Bruns Ingmar bought 20,000 shares for $2.28 per share. The transaction valued at 45,656 led to the insider holds 36,629 shares of the business.
Cam Gallagher bought 687 shares of ZNTL for $1,374 on Feb 11 ’25. On Feb 03 ’25, another insider, Vultaggio Vincent, who serves as the PAO and Interim PFO of the company, sold 2,615 shares for $1.71 each. As a result, the insider received 4,476 and left with 189,826 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 101972336 and an Enterprise Value of -226462656. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.51 while its Price-to-Book (P/B) ratio in mrq is 0.30. Its current Enterprise Value per Revenue stands at -3.359 whereas that against EBITDA is 1.216.
Stock Price History:
The Beta on a monthly basis for ZNTL is 1.81, which has changed by -0.8716094 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, ZNTL has reached a high of $13.24, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is -17.52%, while the 200-Day Moving Average is calculated to be -50.10%.
Shares Statistics:
ZNTL traded an average of 1.44M shares per day over the past three months and 807260 shares per day over the past ten days. A total of 71.28M shares are outstanding, with a floating share count of 54.00M. Insiders hold about 24.81% of the company’s shares, while institutions hold 86.95% stake in the company. Shares short for ZNTL as of 1744675200 were 5265093 with a Short Ratio of 3.66, compared to 1741910400 on 5326118. Therefore, it implies a Short% of Shares Outstanding of 5265093 and a Short% of Float of 14.649999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Zentalis Pharmaceuticals Inc (ZNTL) is currently attracting attention from 7.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $-0.62, with high estimates of $-0.44 and low estimates of $-1.09.
Analysts are recommending an EPS of between $-1.75 and $-3.07 for the fiscal current year, implying an average EPS of $-2.25. EPS for the following year is $-2.25, with 9.0 analysts recommending between $-1.27 and $-3.27.
